

Summary of Potential Annual Savings Due to Biosimilars: CalPERS (All Plans)

	<u>CalPERS</u>
Total Annual Biologic Scripts	33,540
Allowed Rx amount	\$88,770,360
Potential Annual Savings Due to Biosimilars	
Biosimilar Penetration Rate 20%, Biosimilar Discount off of Branded Price 20%	\$3,550,814
Biosimilar Penetration Rate 20%, Biosimilar Discount off of Branded Price 35%	\$6,221,261
Biosimilar Penetration Rate 20%, Biosimilar Discount off of Branded Price 50%	\$8,877,036
Biosimilar Penetration Rate 40%, Biosimilar Discount off of Branded Price 20%	\$7,101,628
Biosimilar Penetration Rate 40%, Biosimilar Discount off of Branded Price 35%	\$12,442,521
Biosimilar Penetration Rate 40%, Biosimilar Discount off of Branded Price 50%	\$17,754,436
Biosimilar Penetration Rate 60%, Biosimilar Discount off of Branded Price 20%	\$10,652,443
Biosimilar Penetration Rate 60%, Biosimilar Discount off of Branded Price 35%	\$18,663,782
Biosimilar Penetration Rate 60%, Biosimilar Discount off of Branded Price 50%	\$26,631,108

Notes:

1. Source of underlying data is CalPERS HCDSS as of June 28, 2013.
2. Based on incurred expenditures from January 1 to December 31, 2012.
3. Excludes insulins and human growth hormones.
4. This table adopts format of Generic Pharmaceutical Association' December 2012 report "State and Federal Summary of Potential Annual Savings Due to Biosimilars," but figures may not be comparable because GPhA's detailed methodology for Medicaid expenditures was not provided.